Loading institutional data...
Loading institutional data...
Held by 867 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $94.25 today, the market must believe free cash flow compounds 7.0%/yr for a decade (off $1.4B normalized FCF).
The market's 7.0% is more optimistic than its 9-yr track record.
2-stage DCF · 0.20B shares · net debt $6.9B
mean 2.0% · volatility σ 16% · implied rate exceeded in 3/7 yrs
Central path = implied 7.0%/yr growth; shaded band = ±1σ (16%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 13% of free cash flow, leaving room to grow it and fund buybacks. Last year: $190M dividends + $487M buybacks = $677M returned on $1.5B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Modest payoff on reinvested capital. Current ROIC on all capital: 3%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~3.2% on $10.1B of debt. Interest last disclosed in FY2017 (no longer broken out).
Cash of $592M fully covers short-term debt of $587M.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.23B 100.0% | $7.68B 100.0% | $7.39B 100.0% | $6.94B 100.0% | $6.83B 100.0% | $6.13B 100.0% | $6.96B 100.0% | $7.93B 100.0% | $7.80B 100.0% | $7.67B 100.0% |
| Cost of Revenue | $2.49B 30.3% | $2.19B 28.5% | $2.08B 28.2% | $2.02B 29.1% | $1.96B 28.7% | $1.82B 29.8% | $1.94B 27.9% | $2.27B 28.6% | $2.13B 27.3% | $2.38B 31.1% |
| Cost of Products | — | — | — | — | — | — | — | — | $2.13B 27.3% | $2.38B 31.1% |
| Selling, General & Admin | $3.26B 39.6% | $2.93B 38.2% | $2.84B 38.4% | $2.76B 39.8% | $2.84B 41.6% | $2.71B 44.3% | $2.81B 40.4% | $3.38B 42.6% | $3.10B 39.8% | $2.94B 38.4% |
| Total Operating Expenses | $7.13B 86.7% | $6.39B 83.3% | $6.12B 82.7% | $6.24B 90.0% | $5.97B 87.4% | $6.04B 98.6% | $5.85B 84.0% | $7.90B 99.6% | $7.00B 89.8% | $6.85B 89.3% |
| Operating Income | $1.10B 13.3% | $1.29B 16.7% | $1.28B 17.3% | $696.3M 10.0% | $860.3M 12.6% | $83.1M 1.4% | $1.11B 16.0% | $33.8M 0.4% | $799.3M 10.2% | $821.1M 10.7% |
| Interest Expense | — | — | — | — | — | — | — | — | $327.5M 4.2% | $357.9M 4.7% |
| Interest & Investment Income | — | — | — | — | — | — | — | — | $2.2M 0.0% | $2.9M 0.0% |
| Other Income (Expense), net | $25.5M 0.3% | -$31.1M -0.4% | -$9.3M -0.1% | -$128.0M -1.8% | $12.2M 0.2% | $23.8M 0.4% | -$4.9M -0.1% | -$15.6M -0.2% | -$9.4M -0.1% | -$66.5M -0.9% |
| Pretax Income | $830.8M 10.1% | $1.04B 13.5% | $1.07B 14.4% | $403.5M 5.8% | $499.0M 7.3% | -$105.2M -1.7% | $880.1M 12.6% | -$271.1M -3.4% | $464.6M 6.0% | $399.6M 5.2% |
| Income Tax Expense | $125.7M 1.5% | $131.4M 1.7% | $42.2M 0.6% | $112.3M 1.6% | $53.5M 0.8% | -$96.0M -1.6% | -$238.0M -3.4% | $108.2M 1.4% | -$1.35B -17.3% | $95.0M 1.2% |
| Net Income | $705.1M 8.6% | $903.8M 11.8% | $1.02B 13.8% | $231.4M 3.3% | $401.6M 5.9% | -$138.9M -2.3% | $1.13B 16.3% | -$379.2M -4.8% | $1.81B 23.2% | $305.9M 4.0% |
| Per Share | ||||||||||
| EPS (Basic) | $3.56 | $4.45 | $4.91 | $1.10 | $1.93 | $-0.67 | $5.52 | $-1.86 | $8.98 | $1.53 |
| EPS (Diluted) | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 |
| Weighted Avg Shares (Basic) | 198.0M | 203.1M | 208.7M | 209.6M | 208.6M | 207.0M | 205.1M | 203.5M | 201.9M | 200.0M |
| Weighted Avg Shares (Diluted) | 198.7M | 203.9M | 209.7M | 210.3M | 210.4M | 207.0M | 206.7M | 203.5M | 203.7M | 202.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 27th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 28.6 | 27.9 | 29.8 | 28.7 | 29.1 | 28.2 | 28.5 | 30.3 |
| SG&A | 42.6 | 40.4 | 44.3 | 41.6 | 39.8 | 38.4 | 38.2 | 39.6 |
| Operating Income | 0.4 | 16.0 | 1.4 | 12.6 | 10.0 | 17.3 | 16.7 | 13.3 |
| Income Tax | 1.4 | -3.4 | -1.6 | 0.8 | 1.6 | 0.6 | 1.7 | 1.5 |
| Net Income | -4.8 | 16.3 | -2.3 | 5.9 | 3.3 | 13.8 | 11.8 | 8.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ZBH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ZBH | $18.7B | 26.6× | 11.7× | 2.3× | 7.2% | 69.7% | 8.6% | 5.6% | 3.5% | 3.4× | 867 |
Peers = companies sharing ZBH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.